Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS
Year: 2019
Type: conference-abstract
Source: Blood
Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, Johns Hopkins University, Johns Hopkins Medicine, Johns Hopkins Hospital, Pennsylvania State University, University of Virginia, Hospital of the University of Pennsylvania, University of Pennsylvania, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, National Institute of Allergy and Infectious Diseases
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2987000329